These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7298269)

  • 21. Platelet monoamine oxidase in schizophrenia with beta-phenylethylamine and benzylamine as substrates.
    Baron M; Perumal AS; Levitt M; Cannova G
    Biol Psychiatry; 1982 Apr; 17(4):479-83. PubMed ID: 7082713
    [No Abstract]   [Full Text] [Related]  

  • 22. Dopamine metabolism in human brain: effect of monoamine oxidase inhibition in vitro by (-)deprenyl and (+) and (-) tranylcypromine.
    Reynolds GP; Riederer P; Rausch WD
    J Neural Transm Suppl; 1980; (16):173-8. PubMed ID: 6776236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tranylcypromine isomers in depressed outpatients: effects on depression, monoamine oxidase inhibition and tyramine pressor response.
    Van de Merwe TJ; Pare CM; Glover V; Sandler M
    Mod Probl Pharmacopsychiatry; 1983; 19():189-202. PubMed ID: 6346066
    [No Abstract]   [Full Text] [Related]  

  • 24. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
    Lee DH; Mendoza M; Dvorozniak MT; Chung E; van Woert MH; Yahr MD
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):189-94. PubMed ID: 2505797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranylcypromine lowers human platelet MAO B activity but not concentration.
    Fritz RR; Malek-Ahmadi P; Rose RM; Denney RM; Abell CW
    Biol Psychiatry; 1983 Jun; 18(6):685-94. PubMed ID: 6871302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet monoamine oxidase-B activity in Parkinson's disease.
    Steventon GB; Sturman SG; Heafield MT; Waring RH; Napier J; Williams AC
    J Neural Transm Park Dis Dement Sect; 1989; 1(4):255-61. PubMed ID: 2597311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple forms of monoamine oxidase in rabbit platelets.
    Edwards DJ; Chang SS
    Life Sci; 1975 Oct; 17(7):1127-34. PubMed ID: 1196003
    [No Abstract]   [Full Text] [Related]  

  • 30. Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy.
    Follmer C
    Expert Rev Neurother; 2014 Jun; 14(6):703-16. PubMed ID: 24852232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
    Kuhn W; Müller T; Gerstner A; Winkel R; Goetz ME
    Can J Neurol Sci; 1998 Aug; 25(3):249-51. PubMed ID: 9706728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
    Green AR; Youdim MB
    Br J Pharmacol; 1975 Nov; 55(3):415-22. PubMed ID: 1203627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L; Nava L; Rizzo M; Piccoli F
    Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
    [No Abstract]   [Full Text] [Related]  

  • 34. Monoamine oxidase inhibitors and their pharmacological significance.
    Sandler M
    Acta Neurol Scand Suppl; 1983; 95():37-41. PubMed ID: 6428147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoamine oxidase B and Parkinson's disease.
    Steventon G; Humfrey C; Sturman S; Waring RH; Williams AC
    Lancet; 1990 Jan; 335(8682):180. PubMed ID: 1967482
    [No Abstract]   [Full Text] [Related]  

  • 37. In vivo relationship between monoamine oxidase type B and alcohol dehydrogenase: effects of ethanol and phenylethylamine.
    Aliyu SU; Upahi L
    Life Sci; 1988; 43(4):345-56. PubMed ID: 3398704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of single doses of tranylcypromine on platelet MAO and amine uptake in normal subjects.
    Gentil V; Alevizos B; Lader M
    Biochem Pharmacol; 1978; 27(8):1197-201. PubMed ID: 697920
    [No Abstract]   [Full Text] [Related]  

  • 39. A phenylethylamine oxidising defect in migraine.
    Sandler M; Youdim MB; Hanington E
    Nature; 1974 Jul; 250(464):335-7. PubMed ID: 4850263
    [No Abstract]   [Full Text] [Related]  

  • 40. Platelet monoamine oxidase activity and plasma levels of non-catecholic phenylethylamines in insulin-dependent diabetic subjects.
    Mosnaim AD; Karoum F; Zeller A; Callaghan OH; Singh SP; Wolf ME
    Clin Chim Acta; 1982 Dec; 126(3):237-42. PubMed ID: 6758984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.